{"title": null, "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2019-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "COVID-19: respuesta inmune y perspectivas terap\u00e9uticas\nRev. peru. med. exp. salud publica ; 37(2):312-319, 2020.\nArtigo em Espanhol | LILACS (Am\u00e9ricas) | ID: grc-741540\nABSTRACTRESUMEN La\n[enfermedad]causada por el nuevo [coronavirus]( [COVID-19]) se caracteriza por presentar [fiebre]y [tos], afectar el [tracto respiratorio]inferior y [estar]asociada con la edad, comorbilidades y [un] [sistema inmune]debilitado. T\u00edpicamente se ha evidenciado linfopenias en los [casos]graves y una desmedida producci\u00f3n de [citocinas]inflamatorias ( [tormenta de citocinas]), lo que explicar\u00eda el [rol]de la respuesta hiperinflamatoria en la [patog\u00e9nesis]de la [COVID-19]. [Las]respuestas inflamatorias secundarias por reinfecciones del [virus]podr\u00edan inducir el aumento o la mejora dependiente de [anticuerpos](ADE, por [sus]siglas en ingl\u00e9s), [un]fen\u00f3meno vir\u00e9mico que podr\u00eda ser [un]mecanismo alternativo de [infecci\u00f3n]celular y que se deber\u00e1 tener en cuenta cuando se dise\u00f1en [vacunas]o inmunoterapias que involucren el est\u00edmulo de [anticuerpos neutralizantes]o el uso de [anticuerpos monoclonales]. Actualmente no existen [vacunas]ni [tratamientos]que demuestren [seguridad]y [eficacia]en [pacientes]con [COVID-19];sin embargo, se espera la conclusi\u00f3n de los resultados de la aplicaci\u00f3n de una [vacuna]de [\u00e1cidos nucleicos] [ARNm](mensajero del [\u00e1cido ribonucleico]) y de [un] [f\u00e1rmaco antiviral](remdisivir) que se encuentran en ensayos cl\u00ednicos fase III. Por el momento la mejor [medida]para evitar la propagaci\u00f3n de la [infecci\u00f3n]es el [aislamiento social]exhaustivo y viene siendo adoptado por varios pa\u00edses seg\u00fan recomendaci\u00f3n de la [Organizaci\u00f3n Mundial de la Salud]( [OMS]). ABSTRACT [Disease]caused by the new [coronavirus]( [COVID-19]) is characterized by [fever], [cough], and [affection]of the lower [respiratory tract]. It is associated with age, comorbidities and a weakened [immune system]. Typically, [lymphopenias]have been evidenced in severe cases and an excessive [production]of inflammatory [cytokines]( [cytokine storm]), which would explain the [role]of the hyperinflammatory response in the [pathogenesis]of [COVID-19]. [Secondary]inflammatory responses from [virus] [reinfections]may induce [antibody-dependent enhancement](ADE), a viremic phenomenon that may be an alternative mechanism of cellular [infection]and should be considered when designing [vaccines]or [immunotherapies]involving the stimulation of [neutralizing antibodies]or the use of [monoclonal antibodies]. Currently, no [vaccines]or [treatments]demonstrate [safety]and [efficacy]in [patients]with [COVID-19]. However, the results from phase III clinical trials which involve the application of an [mRNA](messenger [ribonucleic acid]) [nucleic acid vaccine]and an [antiviral drug](remdisivir), are yet to be concluded. For the [time]being, the best [measure]to prevent the spread of [COVID-19]is by implementing [social isolation], this [measure]has been adopted by several countries as recommended by the [World Health Organization]( [WHO]). [Buscar no Google](https://www.google.com/search?q=\"COVID-19: respuesta inmune y perspectivas terap\u00e9uticas\")\nCole\u00e7\u00f5es: Bases de dados de organismos internacionais Base de dados: LILACS (Am\u00e9ricas) Tipo de estudo: Estudo progn\u00f3stico T\u00f3picos: Vacinas Idioma: Espanhol Revista: Rev. peru. med. exp. salud publica Ano de publica\u00e7\u00e3o: 2020 Tipo de documento: Artigo\nSimilares\nMEDLINE\n...\nLILACS\nLIS", "language": null, "image": null, "pagetype": null, "links": ["#main_container", "#pesquisa", "#footer", "#", "#", "#", "#", "https://politicas.bireme.org/accesibilidad/pt/", "https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/", "javascript:change_language('ar')", "javascript:change_language('zh')", "javascript:change_language('en')", "javascript:change_language('fr')", "javascript:change_language('ru')", "javascript:change_language('es')", "javascript:change_language('pt')", "https://www.who.int/publications/m/item/quick-search-guide-who-covid-19-database", "https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/advanced/?lang=pt", "https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/static/regional/help/pt/guide.pdf", "#", "https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/", "https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/?lang=pt", "https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/?lang=pt&q=au:\"Lozada-Requena, Iv\u00e1n, N\u00fa\u00f1ez Ponce, C\u00e9sar\"", "https://www.facebook.com/sharer.php?u=https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/grc-741540", "https://twitter.com/intent/tweet?text=COVID-19: respuesta inmune y perspectivas terap\u00e9uticas https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/grc-741540", "https://www.linkedin.com/shareArticle?mini=true&url=https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/grc-741540&title=COVID-19: respuesta inmune y perspectivas terap\u00e9uticas - Base de dados da OMS sobre COVID-19", "https://api.whatsapp.com/send?text=COVID-19: respuesta inmune y perspectivas terap\u00e9uticas - Base de dados da OMS sobre COVID-19 - https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/grc-741540", "#mark_ab", null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, "https://www.google.com/search?q=\"COVID-19: respuesta inmune y perspectivas terap\u00e9uticas\"", "javascript:window.print()", "javascript:export_xml_record('grc-741540');", "https://www.google.com/search?q=\"COVID-19: respuesta inmune y perspectivas terap\u00e9uticas\"", "javascript:window.print()", "javascript:export_xml_record('grc-741540');", "mailto:Library@who.int?subject=WHO COVID-19 DB Info", "http://feedback.bireme.org/feedback/?application=iahx&version=2.0\n&lang=pt&site=portal", "http://politicas.bireme.org/terminos/pt/", "http://politicas.bireme.org/privacidad/pt/", "javascript:change_output('rss');", "javascript:;", "javascript:print_page();", "javascript:print_page(true);"]}